{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:01:50Z","timestamp":1776142910368,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD085887"],"award-info":[{"award-number":["R01 HD085887"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.contraception.2023.109951","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T20:35:55Z","timestamp":1673469355000},"page":"109951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-693X","authenticated-orcid":false,"given":"Kimberly K.","family":"Scarsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Smeaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony T.","family":"Podany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine","family":"Olefsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajeeda","family":"Mawlana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khuanchai","family":"Supparatpinyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivaporn","family":"Gatechompol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia M.","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Gadama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharlaa","family":"Badal-Faesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo F.","family":"Belaunzaran-Zamudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie","family":"Mngqibisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2023.109951_bib0001","first-page":"59","article-title":"Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection","volume":"8","author":"Pillay","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.contraception.2023.109951_bib0002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/1471-0528.14408","article-title":"Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis","volume":"124","author":"Sobhy","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2023.109951_bib0003","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2023.109951_bib0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.contraception.2016.03.006","article-title":"Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing","volume":"94","author":"Edelman","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109951_bib0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.contraception.2019.01.003","article-title":"Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index","volume":"99","author":"Natavio","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109951_bib0006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.contraception.2017.01.004","article-title":"Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index","volume":"95","author":"Praditpan","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.109951_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/137192","article-title":"Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz","volume":"2012","author":"Carten","year":"2012","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.contraception.2023.109951_bib0008","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cpt.1848","article-title":"The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam","volume":"108","author":"Wiesinger","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.109951_bib0009","unstructured":"European Medicines Agency. Emergency Contraceptives. October 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/emergency-contraceptives. Accessed April 5, 2022."},{"key":"10.1016\/j.contraception.2023.109951_bib0010","unstructured":"Medicines and Healthcare products Regulatory Agency. Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. September 2016. https:\/\/www.gov.uk\/drug-safety-update\/levonorgestrel-containing-emergency-hormonal-contraception-advice-on-interactions-with-hepatic-enzyme-inducers-and-contraceptive-efficacy. Accessed April, 5 2022."},{"key":"10.1016\/j.contraception.2023.109951_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2023.109951_bib0012","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-020-00898-8","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review","volume":"59","author":"Podany","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2023.109951_bib0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchromb.2018.03.023","article-title":"Development, validation and utilization of a highly sensitive LC-MS\/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma","volume":"1084","author":"Cirrincione","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.contraception.2023.109951_bib0014","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.clpt.6100282","article-title":"Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial","volume":"83","author":"Fletcher","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.109951_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpba.2014.11.011","article-title":"Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC\/MS\/MS","volume":"104","author":"Winchester","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.contraception.2023.109951_bib0016","unstructured":"US Food and Drug Administration. Bioanalytical method validation: guidance for industry. https:\/\/www.fda.gov\/media\/70858\/download. Accessed April, 5 2022."},{"key":"10.1016\/j.contraception.2023.109951_bib0017","unstructured":"Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Addendum 1: female genital grading table for use in microbicide studies. 2004. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/addendum-1-female-genital-grading-table-v1-nov-2007.pdf. Accessed April, 5 2022."},{"key":"10.1016\/j.contraception.2023.109951_bib0018","unstructured":"Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events. 2017. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. Accessed April, 5 2022."},{"key":"10.1016\/j.contraception.2023.109951_bib0019","unstructured":"Manual for expedited reporting of adverse events to DAIDS. Version 2.0. 2010. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/manual-exped-aes-v2_0.pdf. Accessed April, 5 2022."},{"key":"10.1016\/j.contraception.2023.109951_bib0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cpdd.870","article-title":"Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel\/ethinyl estradiol in healthy volunteers","volume":"10","author":"Begley","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.contraception.2023.109951_bib0021","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3851\/IMP3343","article-title":"Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives","volume":"24","author":"Majeed","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.contraception.2023.109951_bib0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","article-title":"Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection","volume":"73","author":"Csajka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.109951_bib0023","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults","volume":"25","author":"Min","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2023.109951_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.109975","article-title":"Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DouobLNG pharmacokinetic study. Contraception","author":"Cirrincione","year":"2023"},{"key":"10.1016\/j.contraception.2023.109951_bib0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/AOG.0000000000004717","article-title":"Double dosing levonorgestrel-based emergency contraception for individuals with obesity: a randomized controlled trial","volume":"140","author":"Edelman","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2023.109951_bib0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/FPC.0000000000000396","article-title":"Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives","volume":"30","author":"Haas","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.contraception.2023.109951_bib0027","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/jac\/dkz298","article-title":"Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART","volume":"74","author":"Neary","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.contraception.2023.109951_bib0028","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cpt.667","article-title":"The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine","volume":"102","author":"Neary","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.109951_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FPC.0000000000000417","article-title":"Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine","volume":"31","author":"Haas","year":"2021","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.contraception.2023.109951_bib0030","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12889-019-7192-4","article-title":"Gender-based violence and engagement in biomedical HIV prevention, care and treatment: a scoping review","volume":"19","author":"Leddy","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.contraception.2023.109951_bib0031","doi-asserted-by":"crossref","first-page":"18845","DOI":"10.7448\/IAS.17.1.18845","article-title":"Intimate partner violence and HIV infection among women: a systematic review and meta-analysis","volume":"17","author":"Li","year":"2014","journal-title":"J Int AIDS Soc"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:22:15Z","timestamp":1757881335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782423000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":31,"alternative-id":["S0010782423000045"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2023.109951","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2023.109951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109951"}}